文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

高亲和力T细胞受体样抗体的合理开发。

Rational development of high-affinity T-cell receptor-like antibodies.

作者信息

Stewart-Jones Guillaume, Wadle Andreas, Hombach Anja, Shenderov Eugene, Held Gerhard, Fischer Eliane, Kleber Sascha, Nuber Natko, Stenner-Liewen Frank, Bauer Stefan, McMichael Andrew, Knuth Alexander, Abken Hinrich, Hombach Andreas A, Cerundolo Vincenzo, Jones E Yvonne, Renner Christoph

机构信息

Division of Structural Biology, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, United Kingdom.

出版信息

Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5784-8. doi: 10.1073/pnas.0901425106. Epub 2009 Mar 23.


DOI:10.1073/pnas.0901425106
PMID:19307587
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2667008/
Abstract

T-cell interaction with a target cell is a key event in the adaptive immune response and primarily driven by T-cell receptor (TCR) recognition of peptide-MHC (pMHC) complexes. TCR avidity for a given pMHC is determined by number of MHC molecules, availability of coreceptors, and TCR affinity for MHC or peptide, respectively, with peptide recognition being the most important factor to confer target specificity. Here we present high-resolution crystal structures of 2 Fab antibodies in complex with the immunodominant NY-ESO-1(157-165) peptide analogue (SLLMWITQV) presented by HLA-A0201 and compare them with a TCR recognizing the same pMHC. Binding to the central methionine-tryptophan peptide motif and orientation of binding were almost identical for Fabs and TCR. As the MW "peg" dominates the contacts between Fab and peptide, we estimated the contributions of individual amino acids between the Fab and peptide to provide the rational basis for a peptide-focused second-generation, high-affinity antibody library. The final Fab candidate achieved better peptide binding by 2 light-chain mutations, giving a 20-fold affinity improvement to 2-4 nM, exceeding the affinity of the TCR by 1,000-fold. The high-affinity Fab when grafted as recombinant TCR on T cells conferred specific killing of HLA-A0201/NY-ESO-1(157-165) target cells. In summary, we prove that affinity maturation of antibodies mimicking a TCR is possible and provide a strategy for engineering high-affinity antibodies that can be used in targeting specific pMHC complexes for diagnostic and therapeutic purposes.

摘要

T细胞与靶细胞的相互作用是适应性免疫反应中的关键事件,主要由T细胞受体(TCR)对肽 - 主要组织相容性复合体(pMHC)复合物的识别所驱动。TCR对给定pMHC的亲和力分别由MHC分子数量、共受体可用性以及TCR对MHC或肽的亲和力决定,其中肽识别是赋予靶标特异性的最重要因素。在此,我们展示了与由HLA - A0201呈递的免疫显性NY - ESO - 1(157 - 165)肽类似物(SLLMWITQV)形成复合物的2种Fab抗体的高分辨率晶体结构,并将它们与识别相同pMHC的TCR进行比较。Fab和TCR与中央甲硫氨酸 - 色氨酸肽基序的结合以及结合方向几乎相同。由于MW“挂钩”主导了Fab与肽之间的接触,我们估计了Fab与肽之间各个氨基酸的贡献,为以肽为重点的第二代高亲和力抗体文库提供了合理依据。最终的Fab候选物通过2个轻链突变实现了更好的肽结合,亲和力提高了20倍,达到2 - 4 nM,比TCR的亲和力高出1000倍。当作为重组TCR移植到T细胞上时,高亲和力Fab赋予了对HLA - A0201/NY - ESO - 1(157 - 165)靶细胞的特异性杀伤作用。总之,我们证明了模拟TCR的抗体亲和力成熟是可能的,并提供了一种工程化高亲和力抗体的策略,可用于靶向特定pMHC复合物以用于诊断和治疗目的。

相似文献

[1]
Rational development of high-affinity T-cell receptor-like antibodies.

Proc Natl Acad Sci U S A. 2009-4-7

[2]
Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.

Immunol Lett. 2009-8-15

[3]
TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity.

J Immunol. 2002-7-15

[4]
Probing the Conformational Dynamics of Affinity-Enhanced T Cell Receptor Variants upon Binding the Peptide-Bound Major Histocompatibility Complex by Hydrogen/Deuterium Exchange Mass Spectrometry.

Biochemistry. 2021-3-23

[5]
Affinity Maturation of a T-Cell Receptor-Like Antibody Specific for a Cytomegalovirus pp65-Derived Peptide Presented by HLA-A*02:01.

Int J Mol Sci. 2021-2-26

[6]
Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.

J Immunol. 2014-12-1

[7]
Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1 tumor-specific peptide.

J Immunother Cancer. 2021-6

[8]
Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.

J Immunother Cancer. 2022-3

[9]
Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.

Cancer Res. 2002-10-15

[10]
Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.

Proc Natl Acad Sci U S A. 2002-7-9

引用本文的文献

[1]
De novo design and structure of a peptide-centric TCR mimic binding module.

Science. 2025-7-24

[2]
design and structure of a peptide-centric TCR mimic binding module.

bioRxiv. 2024-12-20

[3]
Targeting peptide antigens using a multiallelic MHC I-binding system.

Nat Biotechnol. 2024-12-13

[4]
Antigen-specific modulation of chronic experimental autoimmune encephalomyelitis in humanized mice by TCR-like antibody targeting autoreactive T-cell epitope.

Life Sci Alliance. 2025-1

[5]
Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges.

Acta Pharm Sin B. 2024-9

[6]
TCR/CD3-based synthetic antigen receptors (TCC) convey superior antigen sensitivity combined with high fidelity of activation.

Sci Adv. 2024-9-6

[7]
Regulation of temporal cytokine production by co-stimulation receptors in TCR-T cells is lost in CAR-T cells.

Immunother Adv. 2024-6-19

[8]
The Future of TCR-like Antibodies in Diagnosis and Potential Application Targets.

Curr Mol Med. 2025

[9]
Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4/HLA-A∗02:01 complex.

Mol Ther. 2024-3-6

[10]
Challenges and solutions for therapeutic TCR-based agents.

Immunol Rev. 2023-11

本文引用的文献

[1]
Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues.

Proc Natl Acad Sci U S A. 2008-9-30

[2]
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.

J Immunol. 2008-5-1

[3]
The structural dynamics and energetics of an immunodominant T cell receptor are programmed by its Vbeta domain.

Immunity. 2008-2

[4]
The T cell antigen receptor: "The Hunting of the Snark".

Eur J Immunol. 2007-11

[5]
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines.

J Immunol. 2007-11-1

[6]
How a single T cell receptor recognizes both self and foreign MHC.

Cell. 2007-4-6

[7]
Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation.

Autoimmun Rev. 2006-4

[8]
Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function.

Proc Natl Acad Sci U S A. 2005-12-27

[9]
T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide.

Nat Immunol. 2005-11

[10]
T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production.

J Immunol. 2005-6-15

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索